Epigenomic control of the innate immune response

Current Opinion in Pharmacology

Volumn 13, Issue 4, 2013, Pages 582-587

  Stender, Joshua D ^a   Glass, Christopher K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BACTERIUM LIPOPOLYSACCHARIDE; BETA INTERFERON; HISTONE ACETYLTRANSFERASE GCN5; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE 3; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR; MYELOID DIFFERENTIATION FACTOR 88; NUCLEAR RECEPTOR COREPRESSOR; RNA POLYMERASE II; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR PU 1; TUMOR NECROSIS FACTOR;

ARTICLE; BACTERIAL IMMUNITY; CELL SPECIFICITY; ENHANCER REGION; EPIGENETICS; GENE ACTIVATION; HISTONE MODIFICATION; HUMAN; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SEPTIC SHOCK; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

EID: 84885956378     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.06.002     Document Type: Review

References (54)

1. Kumar H, Kawai T, Akira S: Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009, 388:621-625.
2. Beutler B: Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases. Immunol Rev 2009, 227:248-263.
3. Marshak-Rothstein A: Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006, 6:823-835. (Pubitemid 44631651)
4. Caricilli AM, Nascimento PH, Pauli JR, Tsukumo DM, Velloso LA, Carvalheira JB, Saad MJ: Inhibition of toll-like receptor 2 expression improves insulin sensitivity and signaling in muscle and white adipose tissue of mice fed a high-fat diet. J Endocrinol 2008, 199:399-406.
5. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M: Lack of Tolllike receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004, 101:10679-10684. (Pubitemid 38955802)
6. Miller YI, Viriyakosol S, Worrall DS, Boullier A, Butler S, Witztum JL: Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler Thromb Vasc Biol 2005, 25:1213-1219. (Pubitemid 40776611)
7. Mullick AE, Tobias PS, Curtiss LK: Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 2005, 115:3149-3156. (Pubitemid 41567579)
8. Chen R, Alvero AB, Silasi DA, Steffensen KD, Mor G: Cancers take their Toll - the function and regulation of Toll-like receptors in cancer cells. Oncogene 2008, 27:225-233.
9. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H: TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008, 27:218-224.
10. Hawkins RD, Hon GC, Ren B: Next-generation genomics: an integrative approach. Nat Rev Genet 2010, 11:476-486.
11. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K: High-resolution profiling of histone methylations in the human genome. Cell 2007, 129:823-837. (Pubitemid 46802390)
12. Li B, Carey M, Workman JL: The role of chromatin during transcription. Cell 2007, 128:707-719. (Pubitemid 46273570)
13. Musselman CA, Lalonde ME, Cote J, Kutateladze TG: Perceiving the epigenetic landscape through histone readers. Nat Struct Mol Biol 2012, 19:1218-1227.
14. Rosenfeld MG, Lunyak VV, Glass CK: Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 2006, 20:1405-1428. (Pubitemid 43830648)
15. Takeuchi O, Akira S: Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
16. Glass CK, Ogawa S: Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol 2006, 6:44-55. (Pubitemid 43279752)
17. Medzhitov R, Horng T: Transcriptional control of the inflammatory response. Nat Rev Immunol 2009, 9:692-703.
18. Jenuwein T, Allis CD: Translating the histone code. Science 2001, 293:1074-1080. (Pubitemid 32758077)
19. Strahl BD, Allis CD: The language of covalent histone modifications. Nature 2000, 403:41-45. (Pubitemid 30038513)
20. Glatt S, Alfieri C, Muller CW: Recognizing and remodeling the nucleosome. Curr Opin Struct Biol 2011, 21:335-341.
21. Kouzarides T: Chromatin modifications and their function. Cell 2007, 128:693-705. (Pubitemid 46273577)
22. Hargreaves DC, Horng T, Medzhitov R: Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 2009, 138:129-145.
23. Ramirez-Carrozzi VR, Braas D, Bhatt DM, Cheng CS, Hong C, Doty KR, Black JC, Hoffmann A, Carey M, Smale ST: A unifying model for the selective regulation of inducible transcription by CpG islands and nucleosome remodeling. Cell 2009, 138:114-128.
24. Foster SL, Medzhitov R: Gene-specific control of the TLRinduced inflammatory response. Clin Immunol 2009, 130:7-15.
25. Raetz CR, Garrett TA, Reynolds CM, Shaw WA, Moore JD, Smith DC Jr, Ribeiro AA, Murphy RC, Ulevitch RJ, Fearns C et al.: Kdo2- Lipid A of Escherichia coli, a defined endotoxin that activates macrophages via TLR-4. J Lipid Res 2006, 47:1097-1111. (Pubitemid 43764706)
26. Escoubet-Lozach L, Benner C, Kaikkonen MU, Lozach J, Heinz S, Spann NJ, Crotti A, Stender J, Ghisletti S, Reichart D et al.: Mechanisms establishing TLR4-responsive activation states of inflammatory response genes. PLoS Genet 2011, 7:e1002401.
27. Guenther MG, Barak O, Lazar MA: The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol 2001, 21:6091-6101. (Pubitemid 34263509)
28. Guenther MG, Lane WS, Fischle W, Verdin E, Lazar MA, Shiekhattar R: A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev 2000, 14:1048-1057. (Pubitemid 30324419)
29. Yoon HG, Chan DW, Huang ZQ, Li J, Fondell JD, Qin J, Wong J: Purification and functional characterization of the human NCoR complex: the roles of HDAC3, TBL1 and TBLR1. EMBO J 2003, 22:1336-1346. (Pubitemid 36362697)
30. Chen X, Barozzi I, Termanini A, Prosperini E, Recchiuti A, Dalli J, Mietton F, Matteoli G, Hiebert S, Natoli G: Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. Proc Natl Acad Sci USA 2012, 109:E2865-E2874.
31. Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K: The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell 2005, 19:523-534. (Pubitemid 41140009)
32. Sims RJ 3rd, Belotserkovskaya R, Reinberg D: Elongation by RNA polymerase II: the short and long of it. Genes Dev 2004, 18:2437-2468. (Pubitemid 39362887)
33. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, Chandwani R, Marazzi I, Wilson P, Coste H et al.: Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468:1119-1123.
34. Visel A, Blow MJ, Li Z, Zhang T, Akiyama JA, Holt A, Plajzer-Frick I, Shoukry M, Wright C, Chen F et al.: ChIP-seq accurately predicts tissue-specific activity of enhancers. Nature 2009, 457:854-858.
35. Stender JD, Pascual G, Liu W, Kaikkonen MU, Do K, Spann NJ, Boutros M, Perrimon N, Rosenfeld MG, Glass CK: Control of proinflammatory gene programs by regulated trimethylation and demethylation of histone H4K20. Mol Cell 2012, 48:28-38.
36. De Santa F, Narang V, Yap ZH, Tusi BK, Burgold T, Austenaa L, Bucci G, Caganova M, Notarbartolo S, Casola S et al.: Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J 2009, 28:3341-3352.
37. De Santa F, Totaro MG, Prosperini E, Notarbartolo S, Testa G, Natoli G: The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell 2007, 130:1083-1094. (Pubitemid 47410272)
38. Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H et al.: A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012, 488:404-408.
39. Calo E, Wysocka J: Modification of enhancer chromatin: what, how, and why? Mol Cell 2013, 49:825-837.
40. Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, Harp LF, Ye Z, Lee LK, Stuart RK, Ching CW et al.: Histone modifications at human enhancers reflect global cell-typespecific gene expression. Nature 2009, 459:108-112.
41. Trompouki E, Bowman TV, Lawton LN, Fan ZP, Wu DC, DiBiase A, Martin CS, Cech JN, Sessa AK, Leblanc JL et al.: Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regeneration. Cell 2011, 147:577-589.
42. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK: Simple combinations of lineage-determining transcription factors prime cisregulatory elements required for macrophage and B cell identities. Mol Cell 2010, 38:576-589.
43. Mercer EM, Lin YC, Benner C, Jhunjhunwala S, Dutkowski J, Flores M, Sigvardsson M, Ideker T, Glass CK, Murre C: Multilineage priming of enhancer repertoires precedes commitment to the B and myeloid cell lineages in hematopoietic progenitors. Immunity 2011, 35:413-425.
44. Mullen AC, Orlando DA, Newman JJ, Loven J, Kumar RM, Bilodeau S, Reddy J, Guenther MG, DeKoter RP, Young RA: Master transcription factors determine cell-type-specific responses to TGF-beta signaling. Cell 2011, 147:565-576.
45. Ghisletti S, Barozzi I, Mietton F, Polletti S, De Santa F, Venturini E, Gregory L, Lonie L, Chew A, Wei CL et al.: Identification and characterization of enhancers controlling the inflammatory gene expression program in macrophages. Immunity 2010, 32:317-328.
46. Foster SL, Hargreaves DC, Medzhitov R: Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007, 447:972-978. (Pubitemid 46975746)
47. Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, Barrera LO, Van Calcar S, Qu C, Ching KA et al.: Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 2007, 39: 311-318. (Pubitemid 46328487)
48. Rada-Iglesias A, Bajpai R, Swigut T, Brugmann SA, Flynn RA, Wysocka J: A unique chromatin signature uncovers early developmental enhancers in humans. Nature 2011, 470:279-283.
49. Core LJ, Waterfall JJ, Lis JT: Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science 2008, 322:1845-1848.
50. De Santa F, Barozzi I, Mietton F, Ghisletti S, Polletti S, Tusi BK, Muller H, Ragoussis J, Wei CL, Natoli G: A large fraction of extragenic RNA pol II transcription sites overlap enhancers. PLoS Biol 2010, 8:e1000384.
51. Hah N, Danko CG, Core L, Waterfall JJ, Siepel A, Lis JT, Kraus WL: A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells. Cell 2011, 145: 622-634.
52. Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y, Qiu J, Liu W, Kaikkonen MU, Ohgi KA et al.: Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 2011, 474:390-394.
53. Melo CA, Drost J, Wijchers PJ, van de Werken H, de Wit E, Oude Vrielink JA, Elkon R, Melo SA, Leveille N, Kalluri R et al.: eRNAs are required for p53-dependent enhancer activity and gene transcription. Mol Cell 2013, 49:524-535.
54. Ostuni R, Piccolo V, Barozzi I, Polletti S, Termanini A, Bonifacio S, Curina A, Prosperini E, Ghisletti S, Natoli G: Latent enhancers activated by stimulation in differentiated cells. Cell 2013, 152:157-171.